Seedo Corp. Appoints Dr. Yahav Bleicher, A Recognized Expert with Extensive Experience in Extracts, Natural Foods, and Nutraceuticals, to Develop the Company's Pharma Grade Saffron.


TEL AVIV, Israel, May 20, 2021 (GLOBE NEWSWIRE) --  Seedo Corp. (OTCQB: SEDO), today announced the appointment of Dr. Yahav Bleicher, an expert in his field, to be in charge of extracting and developing the company's new line of products.

Dr. Bleicher brings with him decades of experience as a highly trained professional in the natural products' industry, functional foods & beverages, and a unique specialization in nutraceuticals, extracts and application methods of botanicals and nutraceuticals.

Dr. Bleicher is a licensed pharmacist and herbalist whose been researching plants and formulations for years. He owns a degree in biochemistry and agriculture from the Hebrew University in Jerusalem and Israeli Volcanic Institute (ARO) where he led an Israeli invention of the extraction of Omega 3 from plants.

Commenting on the appointment, David Freidenberg, CEO, Seedo Corp., stated: “From a professional perspective, Yahav brings to Seedo Corp. a broad, practical experience with a variety of products, and an in-depth expertise in developing extracts, natural products and nutraceuticals. He is highly respected in his field, and we look forward to working with him in meeting our strategic goals.”

"I'm happy for this opportunity to contribute with my knowledge and vast experience to Seedo's innovation and look forward to a fruitful research and development process" stated Dr. Bleicher."

About Seedo:

Seedo Corp. (OTC: SEDO) is an agritech company that focuses on the research, development, and commercialization of agriculture products. Seedo's technology is aimed at transforming the way agriculture is done by offering a responsible and sustainable way to grow crops in a world confronted by environmental challenges and dwindling earth reserves, diminishing water sources and unstable weather conditions.

Cautionary Note Regarding Forward-Looking Statements

This letter contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to our ability to successfully execute a smooth transition of CFO functions as well as our ability to retain and recruit qualified executives; uncertainties related to, and failure to achieve, the potential benefits and success of our senior management team and organizational structure; our ability to successfully compete in the marketplace; our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Reports on Form 10-Q and in our Annual Report on Form 10-K, including in the sections captioned "Risk Factors" and "Forward Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Media Relations Contact:
David Freidenberg, Chief Executive Officer,
info@saffron.ag
+1 (800) 608-6432

Attachment


Picture1

Tags